Page last updated: 2024-08-24

topotecan and bortezomib

topotecan has been researched along with bortezomib in 12 studies

Research

Studies (12)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (16.67)	29.6817
2010's	9 (75.00)	24.3611
2020's	1 (8.33)	2.80

Authors

Authors	Studies
Lombardo, F; Obach, RS; Waters, NJ	1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Beretta, GL; Brigliadori, G; Corna, E; De Cesare, M; Fabbri, F; Ricotti, L; Rosetti, M; Supino, R; Tesei, A; Ulivi, P; Zoli, W; Zunino, F	1
Kurzrock, R; Subbiah, V; Trent, JC	1
Badgett, TC; Chen, QR; Cheuk, AT; Khan, J; Song, YK; Tsang, PS; Wei, JS	1
Downward, J; Hancock, DC; Howell, M; Kelly, G; Kuznetsov, H; Marani, M; Molina-Arcas, M; Saunders, B; Steckel, M; Warne, PH; Weigelt, B	1
Allen, JW; Gandara, DR; Gitlitz, BJ; Kelly, K; Lara, PN; Mack, PC; Moon, J; Redman, MW; Semrad, TJ	1
Gad, Y; Helgason, T; Hong, DS; Jain, RK; Kurzrock, R; Naing, A; Shi, NY; Wheler, J	1
Babich, JW; Mairs, RJ; Nixon, C; Rae, C; Tesson, M	1
Hsu, CW; Huang, R; Li, S; Sakamuru, S; Xia, M; Zou, C	1
Hirabayashi, K; Kikuta, K; Kondo, T; Noguchi, R; Ono, T; Ozawa, I; Sei, A; Yoshimatsu, Y	1

Reviews

1 review(s) available for topotecan and bortezomib

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

2 trial(s) available for topotecan and bortezomib

Article	Year
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyrazines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Recurrence; Small Cell Lung Carcinoma; Sorafenib; Topotecan; Young Adult	2015
Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies. Cell cycle (Georgetown, Tex.), 2015, Volume: 14, Issue:21 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Computer Simulation; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Molecular Targeted Therapy; Neoplasms; S Phase Cell Cycle Checkpoints; Sirolimus; Texas; Time Factors; Topotecan; Treatment Outcome; Young Adult	2015

Article

Year

Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyrazines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Recurrence; Small Cell Lung Carcinoma; Sorafenib; Topotecan; Young Adult

2015

Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies.

Cell cycle (Georgetown, Tex.), 2015, Volume: 14, Issue:21

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Computer Simulation; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Molecular Targeted Therapy; Neoplasms; S Phase Cell Cycle Checkpoints; Sirolimus; Texas; Time Factors; Topotecan; Treatment Outcome; Young Adult

2015

Other Studies

9 other study(ies) available for topotecan and bortezomib

Article	Year
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15 Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship	2013
Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models. Neoplasia (New York, N.Y.), 2005, Volume: 7, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Camptothecin; Disease Models, Animal; DNA Topoisomerases, Type I; Down-Regulation; Female; Humans; Mice; Mice, Nude; Protease Inhibitors; Pyrazines; RNA, Messenger; S Phase; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Urinary Bladder Neoplasms	2005
Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Intracellular Signaling Peptides and Proteins; Middle Aged; Perivascular Epithelioid Cell Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Retroperitoneal Neoplasms; Sirolimus; Topotecan; TOR Serine-Threonine Kinases; Treatment Failure	2010
Synthetic lethal screen identifies NF-κB as a target for combination therapy with topotecan for patients with neuroblastoma. BMC cancer, 2012, Mar-21, Volume: 12 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Mice; Mice, SCID; Microarray Analysis; Neuroblastoma; NF-kappa B; Pyrazines; RNA, Small Interfering; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays	2012
Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. Cell research, 2012, Volume: 22, Issue:8 Topics: Alleles; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Colonic Neoplasms; Deoxycytidine; DNA Topoisomerases, Type I; GATA2 Transcription Factor; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Mutation; Nuclear Proteins; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; ras Proteins; RNA Interference; RNA, Small Interfering; Topoisomerase I Inhibitors; Topotecan; Transcriptional Activation	2012
Preliminary evaluation of prostate-targeted radiotherapy using (131) I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs. The Journal of pharmacy and pharmacology, 2016, Volume: 68, Issue:7 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cell Proliferation; Disulfiram; Glutamates; Humans; Imidazoles; Iodine Radioisotopes; Male; Molecular Targeted Therapy; Phthalazines; Piperazines; Prostate; Spheroids, Cellular; Thiophenes; Topotecan; Tumor Cells, Cultured; Urea	2016
Identification of Angiogenesis Inhibitors Using a Co-culture Cell Model in a High-Content and High-Throughput Screening Platform. SLAS technology, 2018, Volume: 23, Issue:3 Topics: Angiogenesis Inhibitors; Bortezomib; Cell Line, Transformed; Coculture Techniques; Docetaxel; Drug Evaluation, Preclinical; Endothelium, Vascular; High-Throughput Screening Assays; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mesenchymal Stem Cells; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Signal Transduction; Telomerase; Topotecan	2018
Establishment and characterization of NCC-MFS2-C1: a novel patient-derived cancer cell line of myxofibrosarcoma. Human cell, 2021, Volume: 34, Issue:1 Topics: Aged; Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Depsipeptides; Drug Screening Assays, Antitumor; Drug Tapering; Fibroma; Gemcitabine; Humans; Loss of Function Mutation; Male; Neoplasm Invasiveness; Neurofibromin 1; PTEN Phosphohydrolase; Topotecan	2021